CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).
  
  OVERVIEW OF ACTIVITY
  The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many tumor types. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided oncology healthcare professionals and patients with many additional and beneficial FDA-endorsed treatment options. Although this dynamic appears to be prevalent in many corners of oncology, recent advancements in the management of advanced OC have made it particularly relevant for this area of medicine. Perhaps the largest recent development in OC has been the introduction of PARP inhibitors into the therapeutic milieu, and the emergence of a handful of extremely promising data sets is stimulating significant enthusiasm in the expectation that several more novel approaches may soon become available to practicing clinicians.
  
  These video proceedings from a CME symposium held during the 2018 ASCO Annual Meeting feature discussions with leading researchers with an expertise in ovarian cancer regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Appraise available guideline recommendations and consensus statements regarding the indications for genetic testing in OC, and use the results of these assessments to guide long-term treatment planning.
  • Appreciate available clinical trial data with and approved indications for the use of FDA-approved PARP inhibitors for patients with OC in order to appropriately integrate these agents into routine clinical practice.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy and immunotherapy, and refer appropriate patients for clinical trial participation.
  • Review the mechanisms of action, emerging efficacy data and toxicity profiles of novel targeted agents and immunotherapeutic approaches under investigation in OC, and effectively prioritize clinical trial opportunities for appropriate patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Robert L Coleman, MD
  Professor and Vice Chair, Clinical Research
  Ann Rife Cox Chair in Gynecology
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Genentech, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Contracted Research: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Janssen Biotech Inc, Merck, Roche Laboratories Inc.
  
  Ursula A Matulonis, MD
  Medical Director and Program Leader
  Gynecologic Oncology Program
  Professor of Medicine
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: 2X Oncology, FUJIFILM Pharmaceuticals USA Inc, GeneDx, ImmunoGen Inc, Myriad Genetic Laboratories Inc; Consulting Agreements: 2X Oncology, FUJIFILM Pharmaceuticals USA Inc, GeneDx, ImmunoGen Inc, Merck, Myriad Genetic Laboratories Inc.
  
  Kathleen Moore, MD
  Jim and Christy Everest Endowed Chair in Cancer Research
  Director, Oklahoma TSET Phase I Program
  Stephenson Cancer Center
  Associate Professor, Section of Gynecologic Oncology
  Director, Gynecologic Oncology Fellowship
  Department of Obstetrics and Gynecology
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, Janssen Biotech Inc. Consulting Agreements: Abbott Laboratories, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, GlaxoSmithKline, Incyte Corporation, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Clovis Oncology, ImmunoGen Inc, Merck and Tesaro Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: August 2018
  Expiration date: August 2019